Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
- 441 Downloads
The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC).
We searched PubMed, Embase and the Cochrane Central Register of Controlled Trials databases for relevant trials. Reference lists of original articles and review articles were also examined. Abstracts presented at the ASCO and ESMO meetings were also searched. Studies were evaluated for eligibility and quality, and then, the data were extracted and analyzed. Statistical analyses were conducted by using RevMan 5.1. The primary end point was overall survival (OS). Secondary end points included 1-year survival, time to progression (TTP), overall response rate (ORR) and grade 3–4 toxicity.
Nine randomized controlled trials were identified ultimately. The meta-analysis demonstrated that the survival between GD and platinum-based regimens was comparable according to the pooled HR for overall survival (1.04, 95% CI = 0.96–1.12, p = 0.39) and RR for one-year survival (0.94, 95% CI = 0.84–1.06, p = 0.33). Platinum-based regimens had an advantage in TTP (HR = 1.12, 95% CI = 1.02–1.24, p = 0.02) and ORR (RR = 0.86, 95% CI = 0.74–0.99, p = 0.03). However, GD induced less grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia (RR = 0.36, 95% CI = 0.15–0.86, p = 0.02; RR = 0.35, 95% CI = 0.23–0.53, p = 0.00; RR = 0.68, 95% CI = 0.52–0.88, p = 0.003; RR = 0.53, 95% CI = 0.34–0.82, p = 0.004, respectively). Grade 3–4 diarrhea, sensory neuropathy, fatigue and thrombocytopenia were comparable between the two groups.
GD acquired similar survival with platinum-based regimens in first-line treatment of advanced NSCLC. Platinum-based regimens had an advantage in TTP and ORR with more grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia compared with GD.
KeywordsCarcinoma Non-small cell lung Gemcitabine Docetaxel Platinum Cisplatin Carboplatin
Conflict of interest
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence this work.
- 2.Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer, Part 1: early-stage disease. Oncology (Williston Park) 17:357–364Google Scholar
- 4.NCCN Non-Small Cell Lung Cancer Panel Members (2011) Non-small cell lung cancer. NCCN clinical practice guidelines in oncology version 3, 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- 8.Julian PT Higgins, Douglas G Altman, Jonathan AC Sterne (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (ed) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org
- 11.Rubio JC, Estevez SV, Rivera FV et al (2006) Gemcitabine/Docetaxel (GD) vs Gemcitabine/Cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no. 18S (June 20 Supplement): 17017Google Scholar
- 12.Rubio JC, Estevez SV, Rivera FV et al (2006) A randomized phase IIB trial of gemcitabine and cisplatin (GC) versus gemcitabine and docetaxel (GD) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). an galician lung cancer group study. ESMO annual meeting abstract 2006. 751PGoogle Scholar
- 14.Takiguchi Y, Katakami N, Yoshimori K et al (2004) Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small cell lung carcinoma (NSCLC): a randomized phase II study by the Japan lung cancer cooperative clinical study group. EMSO annual meeting abstract 2004. 635PDGoogle Scholar
- 15.Georgoulias V, Ardavanis A, Tsiafaki X et al (2004) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. ESMO annual meeting abstract 2004, 637PDGoogle Scholar
- 16.Binder D, Beinert T, Schweisfurth H et al (2004) Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial. ESMO Ann Meet Abstr 2004:7071Google Scholar
- 17.Binder D, Sailer V, Schweigert M et al (2002) A randomized phase II study of gemcitabine/docetaxel vs gemcitabine/cisplatin followed by docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002Google Scholar
- 18.Kakolyris S, Tsiafaki X, Agelidou A et al (2002) Preliminary results of a multicentre randomised phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002Google Scholar
- 20.Georgoulias V, Papadakis E, Alexopoulos A et al (1999) Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. ASCO annual meeting abstract 1999, Abstract No:1778Google Scholar
- 23.Rigas JR, Carey M, Dragnev KH et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112. J Clin Oncol 26: May 20 suppl, abstr 8100Google Scholar
- 24.Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143–150PubMedCrossRefGoogle Scholar
- 26.Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no 18S (June 20 Supplement): 17116Google Scholar